Lifeward Ltd. - Ordinary Shares (LFWD)

HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced it has received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") confirming that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) ("Rule").

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its fourth quarter and full year 2025 financial results before the markets open on Wednesday, March 18, 2026.

Clinic days offered at Shirley Ryan AbilityLab, the #1 ranked rehabilitation hospital for 35 consecutive years, with the goal of accelerating personal exoskeleton adoption

IP and technology acquisition is expected to be highly accretive and to advance Lifeward’s position as a diversified biomedical innovation companyWill Expand Lifeward’s portfolio beyond lower-limb solutions, creating a differentiated, whole-body neuro-rehabilitation portfolio Will Strengthen long-term strategic networks with neuro-rehabilitation prescribers, rehabilitation networks, and payers

Reverse split initiated as Lifeward enters strategic partnership agreement and repositions as MedTech innovation company

Aetna joins Humana and United Healthcare in providing Medicare Advantage coverage for beneficiaries who meet medical necessity criteria for the ReWalk Personal Exoskeleton

Positions Lifeward as a MedTech platform with a clear path to cashflow positive and long-term Biotech upside potential

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, announced today that its Board of Directors has appointed Bob Marshall as Chairman of the Board, effective January 1, 2026. He replaces Joseph Turk, who will transition off the Board in connection with his new position at Fresenius Medical Care.

Distribution agreement with Singapore-based Verita Neuro will provide patients the ReWalk Personal Exoskeleton as part of its multi-layered treatment modalities

Humana and UnitedHealthcare, which granted authorization in November, are the two largest Medicare Advantage providers in the U.S., accounting for 47% of all Medicare Advantage enrollees

Approval marks continued progress in expanding reimbursement pathways and accelerating access to advanced personal exoskeleton technology for individuals with spinal cord injury.

Record quarter of ReWalk systems placed for Medicare beneficiaries since fee schedule established 

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its third quarter 2025 financial results before the markets open on Friday, November 14, 2025.

Medicare Advantage claim processed in less than thirty days

Seventh generation of industry-leading ReWalk Exoskeleton is now cleared for commercial launch in the European Union

Achieves record number of ReWalk systems placed for Medicare beneficiaries since fee schedule established

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Almog Adar, who previously served as the Company’s Vice President of Finance and Chief Accounting Officer, has been appointed as the Company’s new Chief Financial Officer.

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its second quarter 2025 financial results before the markets open on Thursday, August 14, 2025.

Expansion adds additional AlterG dealer coverage to 6 countries throughout the Gulf Cooperation Council region

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced the closing of its previously announced public offering of an aggregate of 4,000,000 of the Company’s ordinary shares and accompanying warrants to purchase up to 4,000,000 of the Company’s ordinary shares, at a combined public offering price of $0.65 per ordinary share and associated ordinary warrant. The ordinary warrants have an exercise price of $0.65 per ordinary share, are exercisable immediately upon issuance and will expire on the five-year anniversary of the issuance date.

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced the pricing of a public offering of an aggregate of 4,000,000 of the Company’s ordinary shares and accompanying warrants to purchase up to 4,000,000 of the Company’s ordinary shares, at a combined public offering price of $0.65 per ordinary share and associated ordinary warrant. The ordinary warrants will have an exercise price of $0.65 per ordinary share, will be exercisable immediately upon issuance and will expire on the five-year anniversary of the issuance date. The closing of the offering is expected to occur on or about June 26, 2025, subject to the satisfaction of customary closing conditions.

Decision at the highest levels of appeal in the Medicare process establishes medical necessity of the ReWalk Exoskeleton for enabling paralyzed individuals to stand and walk in everyday environments.

Industry veteran brings 30 years of commercial leadership experience

MARLBOROUGH, Mass., and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward, Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Larry Jasinski, Chief Executive Officer, will make a corporate presentation and host one-on-one meetings with investors at the Sidoti May Virtual Investor Conference, taking place on May 21-22, 2025. Joining him will be Mike Lawless, Chief Financial Officer.

U.S. pipeline of ReWalk opportunities continues to build with over 120 qualified leads in process